Tg Therapeutics (TGTX) Share-based Compensation (2011 - 2026)

Tg Therapeutics' Share-based Compensation history runs 16 years deep, the most recent figure standing at $20.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 33.25% year-over-year to $20.0 million; the TTM figure through Mar 2026 stood at $52.2 million (up 9.48% YoY), while the FY2025 annual figure was $64.7 million, up 52.16% from the prior year.
• Share-based Compensation was $20.0 million for Q1 2026 at Tg Therapeutics, up from $15.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $36.5 million in Q4 2022 to a low of -$1.0 million in Q2 2022.
• Historically, Share-based Compensation has averaged $11.3 million across 5 years, with a median of $9.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation plunged 106.13% in 2022, then jumped 1350.0% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $36.5 million in 2022, then tumbled by 74.18% to $9.4 million in 2023, then increased by 26.23% to $11.9 million in 2024, then jumped by 31.44% to $15.7 million in 2025, then increased by 27.47% to $20.0 million in 2026.
• The last three Share-based Compensation figures came in at $20.0 million (Q1 2026), $15.7 million (Q4 2025), and $200000.0 (Q3 2025), per Business Quant data.